Rapport Therapeutics to present data at 2025 AAN meeting

Rapport Therapeutics (RAPP) announced two encore poster presentations at the 2025 American Academy of Neurology, AAN, Annual Meeting, taking place from April 5 to April 9, 2025, in San Diego, California. The data from these posters was originally presented at the American Epilepsy Society Annual Meeting in December 2024. Rapport will showcase the following posters: Poster #002: Using a receiver operator characteristic analysis, the data confirmed that a 30% reduction in LE frequency was the optimal cut point associated with a clinically meaningful reduction in clinical seizures, regardless of the antiseizure medication initiated, revealing a linear relationship between long episode and clinical seizure frequencies. Poster #003: RAP-219 provided potent, dose-dependent antiseizure effects in pentylenetretrazol and corneal kindling preclinical seizure models, with maximal protection observed with 70% receptor occupancy and RAP-219 mean plasma concentration of 7 ng/mL.